strong and 43 (31.62%) were weak B7-H5 expression. Patients with strong B7-H5 expression had significantly longer overall survival than those with weak expression (median: 16.5 vs 11.5 months, P = .017). TNM staging, tumor location and subsequent chemotherapy were also prognostic factors in these patients. Collectively, B7-H5/CD28H is a co-stimulatory signal pathway, and expression of B7-H5 is associated with improved disease prognosis in patients with pancreatic cancer.
| INTRODUC TI ON
Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancers due to its delayed diagnosis, low surgical resection rate and limited response to current treatment modalities.
1 PDAC is the third leading cause of cancer-related death in the United States, and most patients survive <12 months after diagnosis.
2 Despite decades of efforts, the 5-year overall survival rate remains lower than 10%, 3 and there is an urgent need to develop novel treatment strategies, especially for patients who are refractory to current treatments. Nevertheless, durable responses to immunotherapy have been reported in pancreatic cancer. These responses were often
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associated with significant infiltration of cytotoxic T lymphocytes (CTL) into the tumor tissue, suggesting that effective immunotherapies may improve patient outcomes. 4 Although early clinical trials evaluating the efficacy of immune checkpoint inhibitors, such as those targeting PD1, PD-L1 or CTLA4, failed in patients with pancreatic cancer, [5] [6] [7] new immune targets are promising.
The B7/CD28 families of immune-regulatory ligands/receptors play crucial roles in the acquisition of effector functions of immune system, there has recently been great interest in the role of these molecules in cancer pathogenesis. 8 Notably, B7-H5 (also known as B7-H7, HHLA2) and its receptor CD28H (also known as TMIGD2, IGPR-1) have been identified as the second signaling transduction molecules of T lymphocytes. 9 The specific role of B7-H5/CD28H
receptor/ligand pair in immune signaling is controversial, as it has been reported to have both co-inhibitory and co-stimulatory functions. 10, 11 B7-H5 expression has been reported in numerous cancers, including non-small cell lung cancer, 12 osteosarcoma, 8 melanoma and cancers of the breast, bladder, prostate, esophagus and colon. 13 However, there is lack of detailed studies of B7-H5 expression in pancreatic adenocarcinoma, especially its prognostic value. Aside from clinical TNM stage, few prognostic factors have been identified for the outcomes of pancreatic cancer, 14, 15 highlighting the need to discover better prognostic indicators. In this study, we assessed the biological function of B7-H5/CD28H pathway both in vitro and in vivo, and the expression patterns and clinical significance of this pathway in patients with pancreatic cancer.
| MATERIAL S AND ME THODS

| Cell culture and reagents
Panc-1, Bxpc-3, Miapaca-2 and Aspc-1 pancreatic cancer (PC) cell lines were purchased from ATCC (Manassas, VA, USA). Si187 cell is a primary pancreatic cancer cell line that was derived from a patient with pancreatic ductal adenocarcinoma from our institution.
The Si187 cell line has been propagated continuously for more than 50 generations, and a patent application in China is currently (including all T lymphocytes derived from PBMC) were cultured in improved modified Dulbecco's medium (IMDM; Gibco). All culture media were supplemented with 10% FBS (Gibco) and 1% penicillin/streptomycin (Genom, Hangzhou, China). For Miapaca-2 cells, culture media were supplemented with an additional 2.5% horse serum (Gibco).
| Panc-1 H149 and Panc-1 H5351
Panc-1 cells in the logarithmic growth phase and in good condition
were seeded into a 6-well plate at a density of 1 × 10
5
/mL. When the cells had completely adhered to the wall, the medium was replaced with 2 mL of a fresh DMEM. 
| T lymphocyte functional assays
To evaluate T lymphocyte proliferation, 24-well plates were pre- 
| Assessment of tumor cell viability using the
CCK8 assay
The viability of Panc-1 H149 and Panc-1 H5351 cells in the coculture system was evaluated using the CCK8 cell counting kit. After suspended T lymphocytes and supernatants were removed, serum free media were added, and the viability of tumor cells was assessed using the CCK8 cell counting kit (Keygen Biotech, Nanjing, China), according to the manufacturer's instructions.
| Immunohistochemistry and ELISA
In brief, formalin-fixed paraffin-embedded PDAC tissue samples were cut into 5-μm sections and subjected to heat-induced antigen For the ELISAs, tumor cells and CD8 + naïve T cells co-culture supernatants were collected by centrifugation and stored at −80°C.
Concentrations of IL-2, TNF-a, and IFN-γ were detected using specific ELISA kits (Biolegend), according to the manufacturer's instructions. 
| Flow cytometry
| Real time quantitative polymerase chain reaction (real time qPCR)
Fresh tumor tissue was minced in liquid nitrogen and total RNA was harvested using Trizol LS Reagent (Invitrogen, Carlsbad, CA, USA), and 1 μg total RNA was reverse transcribed into single-stranded cDNA using QuantScript RT Kit (Takara Biotechnology, Dalian, China). The cDNA was used to measure the relative expression of genes using SYBR Premix Ex TaqTM II (Takara) according to the manufacturer's protocol;qPCR assays were performed in 20 μL reactions with Applied Biosystems 7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) using the standard 2 −ΔΔC t method. Table S1 )
| Mouse models and experiments
Six-week old B-NSG (NOD-Prkdcscid IL2rgtm1/Bcgen) mice were purchased from Biocytogen Animal Center (Beijing, China).
Experiments were performed according to the ethical guidelines established by the Ethics Committee of our hospital. Half a million Panc-1 H149 or Panc-1 H5351 cells were re-suspended in 50 μL PBS and subcutaneously injected in B-NSG, then those mice were divided into treatment and control group. After 2 weeks, the treatment group received injections of 1 ×10 6 active healthy human naïve CD8 + T lymphocytes through the tail vein weekly for 6 weeks, while the control group received PBS vehicle injection. One week after the 6 th injection, mice were sacrificed and tumors were harvested for evaluation. 
| Acquisition of human tissue and clinical information
| Statistical analysis
Data were analyzed using SPSS (version 24, SPSS Inc., Chicago, IL, USA) and GraphPad Prism 6 (GraphPad Software, San Diego, CA, USA). Data are presented as mean±standard deviation (SD) or 95%
CI. Continuous variables were analyzed using an unpaired Student's t-test to compare between 2 groups, or one-way ANOVA for multiple groups. Categorical variables were compared using a chi-square test or Fisher exact test, as appropriate. A P value of <.05 was considered to be statistically significant.
| RE SULTS
| B7-H5/CD28H acts as a co-stimulatory pathway in vitro
CD28H was previously found on naïve T cells as a receptor for B7- 
| B7-H5/CD28H acts as a co-stimulatory pathway in vivo
As this B7-H5/CD28H signaling is absent in mice or rat, 10 
| B7-H5 is expressed in human pancreatic cancer and is associated with prognosis
We evaluated the expression pattern of B7-H5 in human PC tumors using immunohistochemistry. The 136 patients with PDAC (Table S2 ) enrolled in this study were divided into 2 groups based on the expression status of B7-H5. (Figure 3A ): A total of 93 patients were defined to have strong expression, while other 43 subjects had weak expression (strong expression rate 68.38%; Table 1 (Table 1) . Multivariable COX analysis further revealed no significant correlations between the survival of pancreatic cancer patients and factors such as gender, age, tumor size, tumor differentiation grade, or serum CA19-9 levels (Table S4) . However, the expression of B7-H5, clinical TNM staging, receipt of adjuvant chemotherapy and tumor location were found to be independent prognostic factors for survival of patients with PDAC. Those who had strong B7-H5 expression, lower TNM staging, completed chemotherapy, and tumors located in the pancreatic body or tail might have a better prognosis (Table 2) .
Furthermore, Kaplan-Meier survival analysis revealed that patients with PDAC who are strong expression for B7-H5 had significantly better median OS than those lacking B7-H5 expression (median OS of 16.5 months in the strong group and 11.5 months in the weak group; log rank P = .017; Figure 3C ). Nevertheless, despite having high B7-H5 expression in PC tumor tissue, patients in the B7-H5 strong expression group had dismal prognosis still.
To elucidate the underlying mechanism, the expression pattern 
| D ISCUSS I ON
Despite recent advances in combination chemotherapies, prognosis for patients with pancreatic cancer remains appallingly poor, even among patients who undergo macroscopically curative resection (5-year survival of 20.7%-23.9%, median survival of 22.3-23.6 months)
followed by adjuvant chemotherapy. 18 In addition to traditional surgical or chemotherapeutical approaches, new treatment strategies, including immunotherapy using checkpoint inhibitors or monoclonal antibodies that have been established as effective cancer therapies for other cancer types, have largely failed to improve survival F I G U R E 3 B7-H5 positivity correlates with prolonged overall survivals in patients with pancreatic cancer. A, Consecutive paraffin slides from two representative pancreatic cancer tissues were evaluated by HE and B7-H5 IHC staining. B7-H5 expression was focal in the cytomembrane and cytoplasm of the cancer cells. Scale bar 25 μm. B, B7-H5 mRNA in fresh patient tumor of both groups were measured by real time quantitative PCR, ß-actin was employed as corresponding control. C, Kaplan-Meier survival analysis was carried out, and the median survival in the B7-H5 strong expression group and the B7-H5 weak expression group was 16.5 and 11.5 months, respectively. (***P < .001; **P < .01; *P < .05; NS no significance)
in pancreatic cancer when used as single agents. 19 Considering the miserable prognosis of this disease, the identification of novel immunotherapeutic targets while taking into account the specific microenvironment of PDAC is of great importance and clinical interest.
20
There is mounting evidence suggesting that immunotherapy, in conjunction with standard of care, can improve the outcomes of patients with pancreatic cancer. 21 Many studies have assessed expressions of inhibitory receptors on exhausted CD8 + T cells, but without specific focus on co-stimulatory molecules. 22 In this study, we demonstrate that B7-H5 can act as a co-stimulatory factor via its receptor, CD28H, which is expressed on T lymphocytes. Evaluation of clinical data revealed that B7-H5 was positively expressed in 68.38% of patients with PDAC, which is in consistence with its expression patterns in other cancers such as breast cancer and osteosarcoma. sults. Yet there remains much to be discovered about this pathway.
However, the underlying mechanism of the regulation of B7-H5 or CD28H remains unknown. In our study, we found that CD28H expression in T lymphocytes was down-regulated after the engagement of T lymphocytes with B7-H5 expressing PC tumor cells. It has also been reported that alterations in gene methylation patterns are responsible to other co-stimulatory signals, such as CD137, which could induce changes in B7-H5 mRNA and protein expression; this was confirmed by pyrosequencing in a series of healthy donors. 24 In conclusion, our findings reveal that B7-H5/CD28H is a costimulatory signal pathway, and expression of B7-H5 is associated with improved disease prognosis in PDAC, which indicate that the B7-H5/CD28H pathway might be a potential immunotherapeutic target in pancreatic cancer. Although there are no available agents to target B7-H5 or CD28H currently, the success of limited number of immunotherapeutic studies on pancreatic cancer has provided 
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